新药时代急性髓系白血病的治疗策略
本文以3例病例为线索,讨论2017年后急性髓系白血病(AML)新药时代的治疗挑战,包括靶向B细胞淋巴瘤2、FLT3、突变型异柠檬酸脱氢酶1/2等新药及CD33、hedgehog通路和脂质体化疗制剂的应用,并为临床医生提供实用指导。
要点
- 诊断和复发时需及时识别可靶向的突变。
- 多种治疗选择并存时需决策选用何种药物。
- 需预见、减轻和管理新药相关常见并发症。
核心结论
- 自2017年以来AML治疗格局发生重大变化,血液科医生需应对可靶向突变识别、药物选择和并发症管理等新挑战。
研究设计与样本
- 本文为病例讨论形式的综述,通过3例病例展示AML管理中的新治疗挑战并提供实践指导。
主要发现
- 新药包括靶向B细胞淋巴瘤2的venetoclax、靶向FLT3的midostaurin和gilteritinib、靶向突变型异柠檬酸脱氢酶1和2的ivosidenib和enasidenib。
- 其他新增药物包括靶向CD33的gemtuzumab ozogomycin重新获批、靶向hedgehog通路的glasdegib以及柔红霉素和阿糖胞苷的脂质体制剂CPX-351。
- 基因组异质性AML有演化倾向,尤其在选择性治疗压力下。
临床怎么用
- 诊断和复发时及时识别可靶向突变。
- 在多种治疗选项中决策选用何种药物。
- 提高对新药相关常见并发症的预见、减轻和管理能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The acute myeloid leukemia (AML) treatment landscape has changed substantially since 2017. New targeted drugs have emerged, including venetoclax to target B-cell lymphoma 2, midostaurin and gilteritinib to target FLT3, and ivosidenib and enasidenib to target mutant isocitrate dehydrogenase 1 and 2, respectively. Other additions include reapproval of gemtuzumab ozogomycin to target CD33, glasdegib to target the hedgehog pathway, and a liposomal formulation of daunorubicin and cytarabine (CPX-351). Genomically heterogeneous AML has a tendency to evolve, particularly under selective treatment pressure. For decades, treatment decisions have largely centered around chemotherapy drug intensity. Physicians now have access to an increasing number of drugs with novel mechanisms of action and distinctive side-effect profiles. Key issues faced by hematologists in this era of new drugs include (1) the timely identification of actionable mutations at diagnosis and at relapse; (2) deciding which drug to use among several therapeutic options; and (3) increasing awareness of how to anticipate, mitigate, and manage common complications associated with these new agents. This article will use 3 case presentations to discuss some of the new treatment challenges encountered in AML management, with the goal of providing practical guidance to aid the practicing physician.
引用
- DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020. PMID: 31765470. doi:10.1182/blood.2019001239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。